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MelanomaDNA integrity in blood is an emerging biomarker in cancer. Here we report a real time PCR approach for the
absolute quantification of four amplicons of 67, 180, 306 and 476 bp in cutaneous melanoma. Three different
integrity indexes (180/67, 306/67 and 476/67 ratios) were tested for their ability to reflect differences in
plasma cell-free DNA (cfDNA) fragmentation in 79 patients affected by cutaneous melanoma and 34 healthy
subjects. All the three integrity indexes showed higher values in melanoma patients in comparison with
healthy subjects.
According to ROC curve analysis, the ratio 180/67 is the most suitable index to be used in cancer patient
selection, even if the combination of the 3 indexes gives the best performance in terms of clinical sensitivity.
The most represented fragments in plasma of melanoma patients are those comprised between 181 and
307 bp, while in healthy subjects there is a prevalence of shorter fragments (67–180 bp).
In conclusion, DNA integrity indexes can be considered suitable parameters for monitoring cfDNA
fragmentation in melanoma patients.tive real time PCR.
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The hypotheses on the origin of cell-free DNA (cfDNA) are still
controversial and details on the exact mechanisms of release are not
completely disclosed [1].
Previous studies demonstrated an increase of circulating cfDNA in
different types of cancer (see Ref. [2] for a review) in comparison to
healthy population. In affected patients, DNA concentration in plasma
can be influenced by tumor stage, size and location [3].
However, these values may also be altered in patients with various
diseases such as trauma, stroke, burns, sepsis, and autoimmune
diseases, thus limiting their value for diagnosis of cancer [1].
Therefore quantitative analyses limited to cfDNA concentration
cannot provide the expected clinical specificity, unless combined with
qualitative alterations of DNA, such as mutations, loss of heterozigosity
(LOH), microsatellite instability and epigenetic changes [3]. The
detection of these biomarkers entails sophisticated techniques due to
their scarcity in plasma if compared towild type sequences and the highsensitivity requested for their detection makes these approaches
challenging for immediate clinical applications.
Circulating cfDNA is released from apoptotic or necrotic cells,
reflecting a differential DNA origin, as well as from living cells through
a mechanism of active release [1,4]. Necrosis is common in solid
malignant tumors and generates a spectrum of DNA fragments with
variable size, due to random digestion by DNases. In contrast, cell death
in normal blood nucleated cells occurs mostly via apoptosis that
generates small and uniform DNA fragments. In support to this
hypothesis, recent studies demonstrated increased DNA length in
plasma from patients with breast [5] and gynecologic cancers in
comparison to healthy subjects [6]. Moreover, DNA characterized by
higher integrity could be evidenced in cancer of the head and neck [7],
prostate [8], kidney [9,10], esophagus [11], nasopharynx [12] and colon
[13]. The test is basedon thehypothesis thatDNA fragments inplasmaof
cancer patients are longer than those detectable in healthy individuals.
Nonetheless, a limited number of studies reported decreased DNA
integrity in cancer patients compared to the healthy population [14–
16] or were unable to demonstrate a difference between cancer and
non-cancer patients [17,18]. This could be due to distinctive features
of different cancer types or to preanalytical and analytical factors [3].
Our attention was focused on the qualitative and quantitative
characterization of cfDNA in patients with cutaneous melanoma.
We adopted a quantitative real time PCR (qPCR) approach based
on the measurement of amplicons of increasing length to determine
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fragmentation.
The method was evaluated by comparing the integrity indexes in
healthy subjects and melanoma patients as well as in pre and post
surgical samples from the same patient.
2. Material and methods
2.1. Patients
Seventy-nine consecutive patients treated at the Department of
Dermatological Sciences of University of Florence, were evaluated for
plasma DNA integrity. Blood samples were collected before primary
tumor resection or, for metastatic patients, before lymph node or
subcutaneous metastases excision.
The group included patients undergoing surgery for in situ
melanoma (n=12) (median: 59.5 range: 39–80 yrs), primary invasive
melanoma (n=57) (median: 67 range: 23–88) and metastatic
melanomas (n=10) (median: 48.5 range: 28–94). In addition, 34
healthy subjects (median: 59 range: 29–85), who voluntarily donated
their blood to be submitted to plasma DNA integrity evaluation, were
chosenas the control population. The clinical pathological parameters of
primary cutaneous invasive melanomas are reported in Table 1.
A subgroup of 21 patients was submitted to a second blood
drawing after 15 days from surgery.
The research protocol was approved by the local ethic board and
all the patients signed an informed consent.
2.2. DNA extraction
A 5 ml aliquot of peripheral blood was collected in EDTA tubes,
transported within 1 h to the laboratory and centrifuged at 4 °C for
10 min (1600 rcf); supernatant was recovered and centrifuged atTable 1
Description of the clinical pathological parameters of primary cutaneous invasive
melanomas (n=57).
Parameter Cases, n (%)
Thickness
≤1 mm 35 (61.4)
1.01–2.0 mm 12 (21.0)
2.01–4.0 mm 7 (12.3)
N4 mm 3 (5.3)
Level
II 12 (21.0)
III 21(36.8)
IV 24 (42.1)
Ulceration
Absent 47 (82.5)
Present 10 (17.5)
Anatomic site
Head and neck 4 (7.0)
Trunk 32 (56.1)
Extremities 17 (29.8)
Acral sites 3 (5.2)
Genital regions 1 (1.7)
Histotype
Superficial spreading melanoma 48 (84.2)
Nodular melanoma 6 (12.8)
Lentigo maligna melanoma 2 (3.5)
Acral-lentiginous melanoma 2 (3.5)
Regression
Absent 40 (70)
Present 17 (30)14,000 rcf for 10 min at 4 °C. Plasma aliquots (600 μl) were stored
at−80 °C before use. DNA was extracted from 500 μl of plasma, using
theQIAampDSPVirusKit (Qiagen, Italy) andRNAse digestion toprevent
RNA interference during assay reaction. Elution volume was 20 μl.
2.3. Plasma DNA integrity indexes by qPCR
The quantity and integrity of the cfDNA circulating in plasma was
evaluated by qPCR targeting the human APP gene (Amyloid Precursor
protein, chr. 21q21.2, accession NM_000484). The assays were
designed in a way that the forward primer and the probe were the
same for all amplicons, whereas the reverse primer varied (see Table 2
for sequences). The length of the amplicons were 67, 180, 306 and
476 bp respectively.
Absolute quantification of the shortest amplicon (67 bp) was
performed in plasma samples to accurately measure the amount of
free circulating DNA per ml plasma [19]. This assay was assumed to be
able to measure the total amount of circulating plasma DNA, including
fragments down to 67 bp in length. Quantification of DNA concen-
tration was obtained by interpolation on an external reference curve
of genomic DNA ranging from 10 to 105 pg/reaction.
DNA extracted from a blood pool of healthy donors, measured
spectrophotometrically (Nanodrop ND1000, Nanodrop, USA) and
evaluated for integrity characteristics by gel electrophoresis on
agarose gel was employed as the standard.
All measurements were performed from a 500 μl-aliquot of
patient's plasma.
qPCR assays were run in the 7900HT Fast Instrument (Applied
Biosystems). Thermal cycling settingwas performed in order to achieve
a comparable qPCR efficiency among the four different amplicons. In
particular thermal conditions included a denaturation step at 95 °C for
10 min and 50 cycles of PCR as follows: i) 15 s at 95 °C and 60 s at 60 °C
for both 67 and 180 bps amplicons, ii) 15 s at 95 °C, 60 s at 56 °C and
60 s at 72 °C for the longer amplicons of 306 and 476 bps. All the
measurements were performed in triplicate on 1 μl of DNA.
Each integrity index was calculated as the ratio between the
absolute concentration of the longer amplicons 180 bp, 306 bp and
476 bp and the total cf DNA amount (amplicon 67 bp).
Alternatively the results were used to evaluate the fraction of
plasma DNA fragments with length varying from 67 to 180 bp, from
181 to 306 bp, from 307 to 476 by subtracting the absolute
concentration of the longer fragment to that of the shorter one.
These results were normalized on the total cfDNA amount and
expressed as a percentage of it.
2.4. Statistical analysis
Statistical analysis was carried out using the SPSS software
package 17.0 (SPSS, Chicago, USA). Statistical differences between
quantitative data were evaluated by Student's t test for unpaired or
paired samples. A p value lower than 0.05 was considered statistically
significant. All the results were reported as mean±standard error
(mean±S.E.).
3. Results
3.1. qPCR efficiency for size specific amplicons
The efficiency each qPCR assay was evaluated in 5 different runs
using five ten-fold dilutions of genomic DNA, ranging from 100 ng to
10 pg. For the 67 bp amplicon the slope=−3.37±0.06 (mean
efficiency=98%) and Y-intercept=38.25±1.8, with coefficient of
correlation always higher than 0.99. Analogously the analysis was
repeated for the other amplicons (Fig. 1) obtaining a perfect
parallelism.
Table 2
Primers and probe sequences.
Amplicon length Hydrolysis probe Forward primer Reverse primers
(5′-FAM, 3′-TAMRA) (5′–3′) (5′–3′)
67 bp ACCCCAGAGGAGCGCCACCTG TCAGGTTGACGCCGCTGT TTCGTAGCCGTTCTGCTGC
180 bp TCTATAAATGGACACCGATGGGTAGT
306 bp GAGAGATAGAATACATTACTGATGTGTGGAT
476 bp TAAAGTAGGACTTAATTGGGTCACAAAC
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cfDNA using a sample volume equivalent to 25 μl of plasma.
3.2. Plasma cfDNA concentration and fragment-size composition in pre-
surgery melanoma and control samples
cfDNA concentrations (mean±SE; ng/ml plasma) in plasma of
healthy subjects are reported in Table 3. The results show a decrease
of cfDNA concentrations as the amplicon dimensions increase in both
healthy and melanoma subjects (Fig. 2A).
Moreover, for each amplicon we found a statistically significant
difference between healthy individuals and patients, with constant
higher values in the melanoma group (Table 3).
Analyzing the integrity indexes 180/67, 306/67 and 476/67,
invariably higher values were found in melanoma patients than in
control subjects (Table 3), (Fig. 2B). Statistically significant differences
can be noticed for all the considered ratios (Table 3).
Within the group of invasive melanomas, no significant correlation
was found between each DNA integrity index and clinical–pathological
parameters, such as Breslow thickness, Clark level, presence of
ulceration, anatomic site, histotype and regression (data not shown).
Calculating the amount of fragments whose dimension is comprised
betweeneachamplicon sizes (see Section2.3),wewere able to evidence
that around 50% of the total cfDNA composition in healthy subjects is
related to the presence of fragments of 67–180 bp of length. On the
contrary, almost 50% of DNA fragments encountered in melanoma
patients before surgery were comprised between 181 and 306. Both
DNA fragment categories showed concentrations significantly different
in the two groups (pb0.0001 and p=0.039, respectively). On the
contrary, the percentage of fragments between 307 and 476 bp (20% in
melanoma patients) was not statistically different between the two
groups (Fig. 2C).45
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Fig. 1. Standard curve plots for the qPCR assays targeting 67, 180, 306, 476 bp
amplicons. Quantification cycle plotted versus log DNA concentration.3.3. Plasma DNA integrity in post surgery blood samples
We studied total plasma DNA concentration 15 days after
melanoma resection in a subgroup of 21 patients (2 in situ, 17
invasive and 2 metastatic melanomas).
No statistical differences were evidenced between pre-surgery
(9.6±2.5, 8.6±2.7, 3.0±0.5 respectively for the 67, 180 and 306 bp
amplicon) and post-surgery (10.8±0.9, 4.0±0.4, 2.4±0.3 respec-
tively for the 67, 180 and 306 bp amplicon) total cfDNA concentration,
with the exception of the longest amplicon resulting 1.2±0.3 pre-
surgery and 0.4±0.1 post-surgery (p=0.025).
A reduction of all the considered integrity indexes could be noticed
after 15 days from tumor removal (pb0.05). In fact, integrity index
180/67 resulted 0.8±0.1 pre-surgery and was reduced to 0.4±0.05
after 15 days (p=0.003). Similarly, the index 306/67 showed a
reduction of about 50% (from 0.4±0.06 to 0.2±0.03; p=0.011) and
the index 476/67 was even more strongly reduced (80% mean
reduction; p=0.012) changing from 0.2±0.06 to 0.05±0.01
(Fig. 3A).
The percentage of fragments between 67 and 180 bp was
significantly enhanced 15 days after surgery (60.5±5.6% versus
37.0±5.8, p=0.004). On the contrary, the percentage of fragments
between 180 and 306 bp was significantly reduced after surgery
(23.6 ±5.2% vs 65.7±12.5%, p=0.016).
A non statistically significant decrease in the percentage of
fragments between 307 and 476 bp was observed after surgery
(45.5±18.9% versus 22.5±3.3, p=0.259) (Fig. 3B).
3.4. Clinical sensitivity and specificity
ROC curve analysis was used to assess the performances of our
evaluation of DNA integrity in melanoma patients and controls. The
area under the ROC curves for melanoma versus healthy patients, the
clinical sensitivities and specificities at chosen cut-off values are
reported in Table 4 for each integrity index. By evaluating the case
study in terms of positivity/negativity on the basis of the chosen cut-
offs, no integrity index is capable by itself to identify more than 68% of
melanoma patients, while combining the 3 parameters we can reach a
higher sensitivity. In fact 74/79 melanoma patients result above the
reported cut-off for at least one parameter, with a total sensitivity of
93.7%.Table 3
cfDNA concentration and integrity indexes (mean±SE) with corresponding p values.
Amplicon size Melanoma patients Controls Probability (P)
(n=67) (n=34)
67 bp 12.4±1..4 8.2±0.9 0.015
180 bp 9.1±0.9 4.4±0.7 b0.001
306 bp 2.9±0.3 1.8±0.2 0.001
476 bp 1.9±0.2 1.0±0.2 0.006
180/67 bp ratio 0.8±0.05 0.5±0.04 b0.001
306/67 bp ratio 0.3±0.03 0.2±0.02 0.008
476/67 bp ratio 0.2±0.03 0.1±0.01 0.002
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Fig. 2. cfDNA concentration (A), integrity indexes (B) and percentages of DNA
fragments of a defined length range (C) in melanoma patients (n=79, black columns)
and healthy subjects (n=34, white columns). Data are reported as mean±S.E.
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Fig. 3. (A) Integrity indexes (mean±S.E.) in melanoma patients (n=21) pre-surgery
(white columns) and 15 days after surgery (black columns). (B) Plasma cell-free DNA
fragment composition. Percentages of DNA fragments of a defined length range pre-
surgery (white columns) and 15 days after surgery (black columns).
Table 4
Area under ROC curves and clinical specificity/sensitivity for the 3 integrity indexes.
Integrity index Area under the curve Cut-off Sensitivity Specificity
180/67 0.75 0.625 68% 72%
306/67 0.56 0.175 68% 40%
476/67 0.59 0.105 62% 56%
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The aim of the present work was to study cfDNA integrity in
cutaneous melanoma, so far not investigated about this aspect.
The study was directed to the quantitative determination of
circulating DNA by means of four qPCR assays differing for the
amplicon length (67, 180, 306 and 476 bp respectively).
Using this approach we confirmed the potential diagnostic ability
of the cfDNA circulating in plasma to discriminate cancer patients
from healthy control subjects. Melanoma patients had higher levels of
cfDNA than healthy subjects (independently from amplicon length),
similarly to already published results for different types of cancer
[2,3].
A statistically significant increase could be evidenced in melanoma
patients when compared to healthy subjects for the three integrity
indexes calculated in this study (180/67, 306/67 and 476/67), in
agreement to already reported data. In fact, notwithstanding a greatheterogeneity in the pre analytical and analytical steps, most of the
papers, based on qPCR approaches to measure DNA fragmentation in
plasma, report an increase of integrity index in tumor patients in
comparison to the healthy population [5–7,11,13].
The construction of a ROC curve allowed the identification of the
ratio 180/67 as the most suitable index to be used in melanoma
patient selection. Nevertheless, the combination of the 3 indexes
(180/67, 306/67 and 476/67) gives the best performance in terms of
clinical sensitivity.
On the basis of our results themost represented fragments in plasma
of melanoma patients are those comprised between 181 and 306 bp,
while in healthy subjects there is a prevalence of shorter fragments (67–
180 bp). It is generally accepted that the 180 bp-fragment reflects
apoptosis, which is the prevalent mechanism of cell death in normal
cells, while necrosis, producing much longer DNA fragments, seems to
occur more frequently in tumor cells [20,21].
Post-surgical melanoma samples show a higher percentage of
small DNA fragments (67–180 bp) together with a lower percentage
of long DNA fragments (181–306 bp) in comparison to the pre-
surgery condition.
In conclusion, DNA integrity indexes resulted suitable parameters
for monitoring cfDNA fragmentation in melanoma patients. As a
perspective in melanoma patients, further studies using DNA integrity
2145P. Pinzani et al. / Clinica Chimica Acta 412 (2011) 2141–2145index to monitor patients' outcome and the effect of therapy are
advisable.
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